{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T22:38:38Z","timestamp":1787697518944,"version":"build-2784847793"},"reference-count":48,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T00:00:00Z","timestamp":1765497600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.ejmech.2025.118478","type":"journal-article","created":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T08:02:49Z","timestamp":1765440169000},"page":"118478","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["N-acylated aminoguanidine-benzenesulfonamides: rational design, synthesis, and dual apoptotic mechanisms of anticancer activity involving VEGFR-2 inhibition and VEGFR-2\u2013independent pathways"],"prefix":"10.1016","volume":"303","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2007-5168","authenticated-orcid":false,"given":"Beata","family":"\u017bo\u0142nowska","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pawe\u0142","family":"Nowak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grzegorz","family":"Stasi\u0142oj\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacek","family":"Jasiecki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"Targo\u0144ska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mateusz","family":"Kogut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Kawiak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2025.118478_bib1","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.ejmech.2025.118478_bib2","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.3390\/ph15101219","article-title":"A review of the biological activity of amidrazone derivatives","volume":"15","author":"Paprocka","year":"2022","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.ejmech.2025.118478_bib3","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.3390\/ph14121229","article-title":"Novel aminoguanidine hydrazone analogues: from potential antimicrobial agents to potent cholinesterase inhibitors","volume":"14","author":"Kr\u00e1tk\u00fd","year":"2021","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.ejmech.2025.118478_bib4","doi-asserted-by":"crossref","DOI":"10.21577\/0103-5053.20230177","article-title":"Aminoguanidine hydrazone derivatives: the antioxidant, antineoplastic profile, and interaction with ctDNA studies","author":"Guimar\u00e3es","year":"2024","journal-title":"J. Braz. Chem. Soc."},{"key":"10.1016\/j.ejmech.2025.118478_bib5","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/0014-2999(94)00637-M","article-title":"Aminoguanidine inhibits both constitutive and inducible nitric oxide synthase isoforms in rat intestinal microvasculature in vivo","volume":"272","author":"Laszlo","year":"1995","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejmech.2025.118478_bib6","doi-asserted-by":"crossref","first-page":"774","DOI":"10.2174\/1573406415666190627103013","article-title":"Identification of novel functionalized carbohydrazonamides designed as chagas disease drug candidates","volume":"16","author":"Nascimento","year":"2020","journal-title":"Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118478_bib7","doi-asserted-by":"crossref","first-page":"3158","DOI":"10.1016\/j.bmc.2018.04.042","article-title":"Novel amidrazone derivatives: design, synthesis and activity evaluation","volume":"26","author":"Zhou","year":"2018","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118478_bib8","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1007\/s00706-018-2197-8","article-title":"Synthesis and evaluation of new amidrazone-derived hydrazides as a potential anti-inflammatory agents","volume":"149","author":"Paprocka","year":"2018","journal-title":"Monatshefte F\u00fcr Chem - Chem Mon"},{"key":"10.1016\/j.ejmech.2025.118478_bib9","doi-asserted-by":"crossref","first-page":"2891","DOI":"10.3390\/molecules27092891","article-title":"Synthesis and structural Study of amidrazone derived Pyrrole-2,5-Dione derivatives: potential anti-inflammatory agents","volume":"27","author":"Paprocka","year":"2022","journal-title":"Molecules"},{"key":"10.1016\/j.ejmech.2025.118478_bib10","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1186\/s12934-018-0976-x","article-title":"Biocatalytic synthesis of acylated derivatives of troxerutin: their bioavailability and antioxidant properties in vitro","volume":"17","author":"Xin","year":"2018","journal-title":"Microb. Cell Fact."},{"key":"10.1016\/j.ejmech.2025.118478_bib11","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1002\/med.21533","article-title":"Lipidic prodrug approach for improved oral drug delivery and therapy","volume":"39","author":"Markovic","year":"2019","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.ejmech.2025.118478_bib12","doi-asserted-by":"crossref","first-page":"42","DOI":"10.3390\/molecules21010042","article-title":"The prodrug approach: a successful tool for improving drug solubility","volume":"21","author":"Jornada","year":"2016","journal-title":"Molecules"},{"key":"10.1016\/j.ejmech.2025.118478_bib13","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1056\/NEJMoa1708539","article-title":"Adjuvant dabrafenib plus trametinib in stage III BRAF-Mutated melanoma","volume":"377","author":"Long","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2025.118478_bib14","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.beha.2019.05.008","article-title":"Venetoclax-based therapies for acute myeloid leukemia","volume":"32","author":"Guerra","year":"2019","journal-title":"Best Pract. Res. Clin. Haematol."},{"key":"10.1016\/j.ejmech.2025.118478_bib15","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2020.564108","article-title":"Clinical review: Navitoclax as a pro-apoptotic and anti-fibrotic agent","volume":"11","author":"Mohamad Anuar","year":"2020","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejmech.2025.118478_bib16","doi-asserted-by":"crossref","DOI":"10.1172\/JCI159839","article-title":"Hypoxia-inducible factors: cancer progression and clinical translation","volume":"132","author":"Wicks","year":"2022","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.ejmech.2025.118478_bib17","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1158\/1078-0432.CCR-22-1366","article-title":"Molecular mechanisms and future implications of VEGF\/VEGFR in cancer therapy","volume":"29","author":"Patel","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2025.118478_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116472","article-title":"Recent advances and future directions on small molecule VEGFR inhibitors in oncological conditions","volume":"272","author":"Thakur","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118478_bib19","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.drudis.2015.07.008","article-title":"Small-molecule kinase inhibitors: an analysis of FDA-approved drugs","volume":"21","author":"Wu","year":"2016","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.ejmech.2025.118478_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113837","article-title":"Sulfonamide derivatives as potential anti-cancer agents and their SARs elucidation","volume":"226","author":"Wan","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118478_bib21","doi-asserted-by":"crossref","first-page":"39772","DOI":"10.1021\/acsomega.5c03503","article-title":"Novel sulfonamide derivatives as anticancer agents, VEGFR-2 inhibitors, and apoptosis triggers: design, synthesis, and computational studies","volume":"10","author":"Al-Ziyadi","year":"2025","journal-title":"ACS Omega"},{"key":"10.1016\/j.ejmech.2025.118478_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2024.107728","article-title":"Novel benzenesulfonamides as dual VEGFR2\/FGFR1 inhibitors targeting breast cancer: design, synthesis, anticancer activity and in silico studies","volume":"152","author":"Hassan","year":"2024","journal-title":"Bioorganic Chem"},{"key":"10.1016\/j.ejmech.2025.118478_bib23","doi-asserted-by":"crossref","first-page":"772","DOI":"10.3390\/biomedicines13040772","article-title":"Sulfonamides a promising hit for cancer therapy through VEGFR-2 inhibition","volume":"13","author":"Charissopoulos","year":"2025","journal-title":"Biomedicines"},{"key":"10.1016\/j.ejmech.2025.118478_bib24","doi-asserted-by":"crossref","first-page":"19101","DOI":"10.3390\/molecules201019101","article-title":"Synthesis, molecular structure, metabolic stability and QSAR studies of a novel series of anticancer N-Acylbenzenesulfonamides","volume":"20","author":"\u017bo\u0142nowska","year":"2015","journal-title":"Molecules"},{"key":"10.1016\/j.ejmech.2025.118478_bib25","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1016\/j.ejmech.2017.11.005","volume":"143","author":"\u017bo\u0142nowska","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118478_bib26","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1023\/A:1010662905549","article-title":"Low pO2 and \u03b2-Estradiol Induce VEGF in MCF-7 and MCF-7-5C cells: relationship to in vivo Hypoxia","volume":"67","author":"Maity","year":"2001","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.ejmech.2025.118478_bib27","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1007\/s12272-025-01545-1","article-title":"Targeting vascular endothelial growth receptor-2 (VEGFR-2): structural biology, functional insights, and therapeutic resistance","volume":"48","author":"Shah","year":"2025","journal-title":"Arch Pharm. Res. (Seoul)"},{"key":"10.1016\/j.ejmech.2025.118478_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.medidd.2019.100009","article-title":"Vascular Endothelial Growth Factor Receptor (VEGFR-2)\/KDR inhibitors: medicinal chemistry perspective","volume":"2","author":"Modi","year":"2019","journal-title":"Med Drug Discov"},{"key":"10.1016\/j.ejmech.2025.118478_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2025.108182","article-title":"New molecular hybrids integrated with quinoxaline and pyrazole structural motifs: VGFR2 inhibitors and apoptosis inducers","volume":"156","author":"Ismail","year":"2025","journal-title":"Bioorganic Chem"},{"key":"10.1016\/j.ejmech.2025.118478_bib30","doi-asserted-by":"crossref","first-page":"12896","DOI":"10.1039\/D5RA00526D","article-title":"Targeting VEGFR-2 in breast cancer: synthesis and in silico and in vitro characterization of quinoxaline-based inhibitors","volume":"15","author":"Eissa","year":"2025","journal-title":"RSC Adv."},{"key":"10.1016\/j.ejmech.2025.118478_bib31","series-title":"0601 Chemical Computing Group ULC, 910-1010 Sherbrooke St. W., Montreal, QC H3A 2R 2025","year":"2024"},{"key":"10.1016\/j.ejmech.2025.118478_bib32","doi-asserted-by":"crossref","unstructured":"Passaro S, Corso G, Wohlwend J, Reveiz M, Thaler S, Somnath VR, et al. Boltz-2: towards Accurate and Efficient Binding Affinity Prediction 2025:2025 .06.14.659707. https:\/\/doi.org\/10.1101\/2025.06.14.659707.","DOI":"10.1101\/2025.06.14.659707"},{"key":"10.1016\/j.ejmech.2025.118478_bib33","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0325255","article-title":"Multiscale computational evaluation of Vitex trifolia phytochemicals as VEGFR2 inhibitors for targeted breast cancer therapy","volume":"20","author":"Fatima","year":"2025","journal-title":"PLoS One"},{"key":"10.1016\/j.ejmech.2025.118478_bib34","first-page":"53","article-title":"Syntheses of a new series of N-Amino-N\"-(benzenesulphonyl)guanidine derivatives with potential antitumor activity","volume":"77","author":"S\u0142awi\u0144ski","year":"2003","journal-title":"Pol. J. Chem."},{"key":"10.1016\/j.ejmech.2025.118478_bib35","doi-asserted-by":"crossref","first-page":"13704","DOI":"10.3390\/molecules190913704","article-title":"Synthesis and anti-yeast evaluation of novel 2-Alkylthio-4-chloro-5-methyl-N-[imino-(1-oxo-(1H)-phthalazin-2-yl)methyl]benzenesulfonamide derivatives","volume":"19","author":"S\u0142awi\u0144ski","year":"2014","journal-title":"Molecules"},{"key":"10.1016\/j.ejmech.2025.118478_bib36","doi-asserted-by":"crossref","first-page":"808","DOI":"10.3390\/molecules21060808","article-title":"Novel 5-Substituted 2-(Aylmethylthio)-4-chloro-N-(5-aryl-1,2,4-triazin-3-yl)benzenesulfonamides: synthesis, molecular structure, anticancer activity, apoptosis-inducing activity and metabolic stability","volume":"21","author":"\u017bo\u0142nowska","year":"2016","journal-title":"Molecules"},{"key":"10.1016\/j.ejmech.2025.118478_bib37","doi-asserted-by":"crossref","first-page":"249","DOI":"10.2478\/s11658-013-0087-y","article-title":"U937 variant cells as a model of apoptosis without cell disintegration","volume":"18","author":"Stasi\u0142oj\u0107","year":"2013","journal-title":"Cell. Mol. Biol. Lett."},{"key":"10.1016\/j.ejmech.2025.118478_bib38","series-title":"AAT Bioquest","year":"2025"},{"key":"10.1016\/j.ejmech.2025.118478_bib39","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1063\/1.445869","article-title":"Comparison of simple potential functions for simulating liquid water","volume":"79","author":"Jorgensen","year":"1983","journal-title":"J. Chem. Phys."},{"key":"10.1016\/j.ejmech.2025.118478_bib40","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/nmeth.4067","article-title":"CHARMM36m: an improved force field for folded and intrinsically disordered proteins","volume":"14","author":"Huang","year":"2017","journal-title":"Nat. Methods"},{"key":"10.1016\/j.ejmech.2025.118478_bib41","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1002\/jcc.21367","article-title":"CHARMM general force field: a force field for drug-like molecules compatible with the CHARMM all-atom additive biological force fields","volume":"31","author":"Vanommeslaeghe","year":"2010","journal-title":"J. Comput. Chem."},{"key":"10.1016\/j.ejmech.2025.118478_bib42","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1002\/jcc.24829","article-title":"CHARMM-GUI ligand Reader & Modeler for CHARMM force field generation of small molecules","volume":"38","author":"Kim","year":"2017","journal-title":"J. Comput. Chem."},{"key":"10.1016\/j.ejmech.2025.118478_bib43","series-title":"Gaussian 16, Revision C.01","author":"Frisch","year":"2016"},{"key":"10.1016\/j.ejmech.2025.118478_bib44","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.softx.2015.06.001","article-title":"GROMACS: high performance molecular simulations through multi-level parallelism from laptops to supercomputers","volume":"1\u20132","author":"Abraham","year":"2015","journal-title":"SoftwareX"},{"key":"10.1016\/j.ejmech.2025.118478_bib45","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1063\/1.447334","article-title":"A unified formulation of the constant temperature molecular dynamics methods","volume":"81","author":"Nos\u00e9","year":"1984","journal-title":"J. Chem. Phys."},{"key":"10.1016\/j.ejmech.2025.118478_bib46","doi-asserted-by":"crossref","DOI":"10.1103\/PhysRevLett.90.075503","article-title":"Predicting crystal structures: the Parrinello-Rahman method revisited","volume":"90","author":"Marto\u0148\u00e1k","year":"2003","journal-title":"Phys. Rev. Lett."},{"key":"10.1016\/j.ejmech.2025.118478_bib47","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1021\/ct700200b","article-title":"P-LINCS: a parallel Linear constraint solver for molecular simulation","volume":"4","author":"Hess","year":"2008","journal-title":"J Chem Theory Comput"},{"key":"10.1016\/j.ejmech.2025.118478_bib48","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1002\/jcc.540130805","article-title":"Settle: an analytical version of the SHAKE and RATTLE algorithm for rigid water models","volume":"13","author":"Miyamoto","year":"1992","journal-title":"J. Comput. Chem."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523425012437?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523425012437?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T04:48:25Z","timestamp":1781326105000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523425012437"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":48,"alternative-id":["S0223523425012437"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2025.118478","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"N-acylated aminoguanidine-benzenesulfonamides: rational design, synthesis, and dual apoptotic mechanisms of anticancer activity involving VEGFR-2 inhibition and VEGFR-2\u2013independent pathways","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2025.118478","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"118478"}}